Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motys in knee osteoarthritis
NCT04632966Phase 1Unknown
- Sponsor
- Bioventus
- Start
- Feb 2021
- Primary completion
- Sep 2022
- Modality
- Biologic, RMAT (Regenerative Medicine Advanced Therapy)
- Countries
- 1
01
Overview
Phase 1, open-label trial of motys in knee osteoarthritis (OA) (2 arms), sponsored by Bioventus. Primary endpoint: Incidence of local and systemic treatment emergent adverse events (AEs). Status: unknown.
02
Drugs
motys
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04632966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632966.